Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03841838
Other study ID # 19-03
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 23, 2019
Est. completion date May 9, 2019

Study information

Verified date March 2019
Source University of the Pacific
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many adults in the United States regularly consumer energy drinks. Currently, the safety of energy drinks is still questionable and there are many reports associating energy drinks with adverse events including hospitalizations and deaths. Previous research shows that energy drink can affect heart rhythm and elevate blood pressure. However, these studies use a higher volume (32 ounces) of energy drinks than those available in the market (24 ounces). The purpose of this study is to study if 24-ounce energy drinks can significantly affect heart rhythm and elevate blood pressure when compared to a placebo.


Description:

The study is a randomized, double blind, controlled, crossover study comparing the effect of energy drinks and placebo on cardiovascular parameters including heart rhythm and blood pressure.

Subjects who contact the PI for interest in study participation will be scheduled a time to study facility for initial evaluation on eligibility criteria. At initial evaluation, participants will be informed about the study details, presented with Informed Consent Document (ICD), and be asked to sign the appropriate forms voluntarily if they decide to participate. Once consented, participants will be asked a series of questions and screened for blood pressure and heart rhythm parameters to determine eligibility to enroll. If patient is eligible to enroll, they will be allocated a randomized identification number.

Participants will be randomly assigned to consume either two-12 oz bottles of energy drink and two-12 oz bottles of control drink on 2 separate days. The study will occur over approximately 8 days with each session taking about 5 hours per day. Each session will have 6 days between each other.

Participants will be expected to refrain from any products containing caffeine or alcohol 48 hours and fast 10 hours before each study visit. At the beginning of each study visit, baseline measurements of ECG, blood pressures, and heart rate will be obtained prior to consuming study drinks. Repeat measurements will be obtained every 60 minutes after consumption over 4 hours.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 9, 2019
Est. primary completion date May 9, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Healthy male or female adults 18-40 years old

- Participants must be willing to refrain from caffeine and alcohol use 48 hours prior to each study day

- Participants must be willing to fast 10 hours prior to each study day

- Participants must have health insurance

Exclusion Criteria:

- Corrected QT (QTc) interval greater than 450 milliseconds (ms). QTc will be determined on the ECG obtained during initial screening appointment.

- Blood pressure at initial screening appointment greater than 140/90 mmHg.

- Presence of any known medical condition confirmed through participant interview

- Concurrent use of ANY medication taken on a daily basis, to include herbal products or supplements (exception include oral contraceptives that will be allowed if taking for longer than 1 month)

- Current smokers or those who have smoked any cigarettes within the past month

- Pregnant or currently breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Energy drink
Two 12 oz bottles of commercially available energy drink
Placebo drink
Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.

Locations

Country Name City State
United States University of Pacific Stockton California

Sponsors (1)

Lead Sponsor Collaborator
University of the Pacific

Country where clinical trial is conducted

United States, 

References & Publications (6)

Elitok A, Öz F, Panc C, Sarikaya R, Sezikli S, Pala Y, Bugan ÖS, Ates M, Parildar H, Ayaz MB, Atici A, Oflaz H. Acute effects of Red Bull energy drink on ventricular repolarization in healthy young volunteers: a prospective study. Anatol J Cardiol. 2015 Nov;15(11):919-22. doi: 10.5152/akd.2015.5791. Epub 2015 Mar 5. — View Citation

Fletcher EA, Lacey CS, Aaron M, Kolasa M, Occiano A, Shah SA. Randomized Controlled Trial of High-Volume Energy Drink Versus Caffeine Consumption on ECG and Hemodynamic Parameters. J Am Heart Assoc. 2017 Apr 26;6(5). pii: e004448. doi: 10.1161/JAHA.116.004448. — View Citation

Hajsadeghi S, Mohammadpour F, Manteghi MJ, Kordshakeri K, Tokazebani M, Rahmani E, Hassanzadeh M. Effects of energy drinks on blood pressure, heart rate, and electrocardiographic parameters: An experimental study on healthy young adults. Anatol J Cardiol. 2016 Feb;16(2):94-9. doi: 10.5152/akd.2015.5930. Epub 2015 Mar 23. — View Citation

Phan JK, Shah SA. Effect of caffeinated versus noncaffeinated energy drinks on central blood pressures. Pharmacotherapy. 2014 Jun;34(6):555-60. doi: 10.1002/phar.1419. Epub 2014 Mar 19. — View Citation

Shah SA, Chu BW, Lacey CS, Riddock IC, Lee M, Dargush AE. Impact of Acute Energy Drink Consumption on Blood Pressure Parameters: A Meta-analysis. Ann Pharmacother. 2016 Oct;50(10):808-15. doi: 10.1177/1060028016656433. Epub 2016 Jun 23. — View Citation

Shah SA, Occiano A, Nguyen TA, Chan A, Sky JC, Bhattacharyya M, O'Dell KM, Shek A, Nguyen NN. Electrocardiographic and blood pressure effects of energy drinks and Panax ginseng in healthy volunteers: A randomized clinical trial. Int J Cardiol. 2016 Sep 1;218:318-323. doi: 10.1016/j.ijcard.2016.05.007. Epub 2016 May 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary QTc interval Maximum change in QTc interval from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Primary Central systolic blood pressure Maximum change in central systolic blood pressure from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Secondary QT interval Maximum change in QT interval from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Secondary PR interval Maximum change in PR interval from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Secondary QRS duration Maximum change in QRS duration from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Secondary Heart rate Maximum change in heart rate from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Secondary Central diastolic blood pressure Maximum change in central diastolic blood pressure from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Secondary Peripheral systolic and diastolic blood pressure Maximum change in peripheral systolic and diastolic blood pressures in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
Secondary Augmentation index Maximum change in augmentation index from baseline in each of 2 arm Measurements are obtained at baseline and every 60 minutes after study drink consumption over 4 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04098172 - Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR N/A